License and Asset Purchase Agreements (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 USD ($)	Jan. 11, 2021 USD ($)	Jul. 27, 2020 USD ($) installment	Mar. 18, 2020	Nov. 30, 2014
Deferred Revenue Arrangement [Line Items]
Gain on sale of priority review voucher		$ 0	$ 6,300
Payments for royalties		146	0
Merck | Licensing and collaboration revenue
Deferred Revenue Arrangement [Line Items]
Grant revenue		10	168
Merck | Royalty revenue
Deferred Revenue Arrangement [Line Items]
Grant revenue		220	0
License and Collaborative Arrangement | Merck
Deferred Revenue Arrangement [Line Items]
Collaborative arrangement development milestone payments		14,000
Collaborative arrangement second indication development milestone payments		8,500
Collaborative arrangement tiered sales milestone payments		80,000
Net product sales milestone		$ 1,000,000
Value of PRV company is entitled to								60.00%
Value of PRV liability							40.00%
Value of PRV						$ 35,700
License and Collaborative Arrangement | Merck | Held-for-sale or Disposed of by Sale | PRV Transfer Agreement
Deferred Revenue Arrangement [Line Items]
Gross proceeds from sale						$ 60,000
Number of installments | installment						2
Cash from sale	$ 34,000
Consideration receivable					$ 26,000
Gain on sale of priority review voucher			6,300
Costs incurred from sale			$ 1,500
License and Collaborative Arrangement | Merck | Minimum
Deferred Revenue Arrangement [Line Items]
Royalty obligation percent of annual product net sales		10.00%
License and Collaborative Arrangement | Merck | Maximum
Deferred Revenue Arrangement [Line Items]
Royalty obligation percent of annual product net sales		12.00%
Ammonett
Deferred Revenue Arrangement [Line Items]
Upfront payments				$ 3,500
Acquisition development milestone payments				17,000
Acquisition specific milestone payments				14,000
Acquisition sales milestone payments				$ 55,000